A Study of DPC 817 in HIV-Infected Males
- Conditions
- HIV Infections
- Registration Number
- NCT00040274
- Lead Sponsor
- Pharmasset
- Brief Summary
The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.
- Detailed Description
The study will consist of two parts. Patients in Part A will receive a single dose of DPC 817 on two separate occasions and a placebo (a solution or tablet without the drug) on one occasion. Patients in Part B will receive two separate doses of DPC 817. Patients will be admitted to the clinical study unit the day before dosing (Day -1) and remain there for at least 48 hours after taking the study drug. Patients will return to the clinical study unit on Day 8 and Day 28 following the dose in the last treatment period. During the study there will be medical and medication histories taken, physical examinations, vital sign measurements, and routine clinical laboratory tests.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
University of North Carolina Hospitals
🇺🇸Chapel Hill, North Carolina, United States
3ClincalResearch Center
🇩🇪Berlin, Germany